BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2019 9:19:18 AM | Browse: 817 | Download: 1522
 |
Received |
|
2019-05-09 01:18 |
|
Peer-Review Started |
|
2019-05-10 03:09 |
|
To Make the First Decision |
|
2019-06-17 01:14 |
|
Return for Revision |
|
2019-06-17 07:06 |
|
Revised |
|
2019-07-09 09:38 |
|
Second Decision |
|
2019-07-12 10:13 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-07-19 15:24 |
|
Articles in Press |
|
2019-07-19 15:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-08-19 06:34 |
|
Publish the Manuscript Online |
|
2019-08-21 09:19 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Ustekinumab: ‘Real-world’ outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Peter Hoffmann, Johannes Krisam, Cyrill Wehling, Petra Kloeters-Plachky, Yvonne Leopold, Nina Belling and Annika Gauss |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peter Hoffmann, MD, Doctor, Doctor, Gastroenterology and Hepatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg 69120, Germany. peter.hoffmann@med.uni-heidelberg.de |
| Key Words |
real-world; ustekinumab; Crohn’s disease; NOD; ; |
| Core Tip |
Real-world data on ustekinumab in Crohn’s disease are scarce. This is a retrospective monocentric study. Patients with Crohn's disease who began ustekinumab therapy at a tertiary referral centre between 2016 and 2018 were included. The primary study endpoint was combined steroid-free clinical remission or response at 24 ± 6 wk of ustekinumab therapy. Fifty-seven patients were included in the study. Twenty patients (35.1%) achieved remission and 6 (10.5%) achieved a clinical response. Male sex, extraintestinal manifestations and the use of steroids at baseline were predictors of nonresponse to ustekinumab therapy. In a ‘real-world’ treatment-refractory cohort of patients with Crohn's disease, ustekinumab appeared efficacious and safe. |
| Publish Date |
2019-08-21 09:19 |
| Citation |
Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A. Ustekinumab: ‘Real-world’ outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol 2019; 25(31): 4481-4492 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i31/4481.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i31.4481 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
